Yura
★    

Belarus,
2017-12-08 09:48
(2323 d 16:28 ago)

Posting: # 18045
Views: 3,925
 

 alpha correction [RSABE / ABEL]

Hello everybody
How to calculate scABEL.ad (alpha = 0.05, CV = 0.3043689, design = "2x3x3", theta0 = 0.77058, regulator = "EMA", n = c (15,15,15)) if the point estimate is not in [0.80 ; 1.25] (SWR = 0.298 [0.79755; 1.25385])? :confused:
with respect :-)
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2017-12-08 13:33
(2323 d 12:43 ago)

@ Yura
Posting: # 18046
Views: 3,288
 

 theta0 within PE-constraints [theta1, theta2]

Hi Yura,

❝ How to calculate scABEL.ad (alpha = 0.05, CV = 0.3043689, design = "2x3x3", theta0 = 0.77058, regulator = "EMA", n = c (15,15,15)) if the point estimate is not in [0.80 ; 1.25] (SWR = 0.298 [0.79755; 1.25385])? :confused:


Note the error message thrown by scABEL.ad():

library(PowerTOST)
scABEL.ad(alpha=0.05, CV=0.3043689, design="2x3x3", theta0=0.77058,
          regulator="EMA", n=c(15,15,15))
Error in scABEL.ad(alpha = 0.05, CV = 0.3043689, design = "2x3x3", theta0 = 0.77058,  :
  theta0 must be within [theta1, theta2]


See the man-page of scABEL.ad():

theta0

‘True’ or assumed bioavailability ratio. Defaults to 0.90 if not given explicitly.


theta1

Conventional lower ABE limit to be applied in the mixed procedure if CVwR==CVswitch. Also lower limit for the point estimate constraint. Defaults to 0.80 if not given explicitly.


theta2

Conventional upper ABE limit to be applied in the mixed procedure if CVwR==CVswitch. Also upper limit for the point estimate constraint. Defaults to 1.25 if not given explicitly.


The purpose of scABEL.ad() is to iteratively adjust α to control the Type I Error either before the study (and see how power is affected with the argument details=TRUE) or post hoc when the T/R-ratio is already known. In both cases ABEL cannot be shown if theta0 would be outside the PE-constraints theta1, theta2 (0.80, 1.25). Hence, modifying your example the most extreme case (theta0=theta1=1/theta2) would be:

library(PowerTOST)
scABEL.ad(alpha=0.05, CV=0.3043689, design="2x3x3", theta0=0.8,
          regulator="EMA", n=c(15,15,15))

+++++++++++ scaled (widened) ABEL ++++++++++++
         iteratively adjusted alpha
   (simulations based on ANOVA evaluation)
----------------------------------------------
Study design: 2x3x3 (TRR|RTR|RRT)
log-transformed data (multiplicative model)
1,000,000 studies in each iteration simulated.

CVwR 0.3044, n(i) 15|15|15 (N 45)
Nominal alpha                 : 0.05
True ratio                    : 0.8000
Regulatory settings           : EMA (ABEL)
Switching CVwR                : 0.3
Regulatory constant           : 0.76
Expanded limits               : 0.7975 ... 1.2538
Upper scaling cap             : CVwR > 0.5
PE constraints                : 0.8000 ... 1.2500
Empiric TIE for alpha 0.0500  : 0.06805
Power for theta0 0.8000       : 0.076
Iteratively adjusted alpha    : 0.03616
Empiric TIE for adjusted alpha: 0.05000

Power for theta0 0.8000       : 0.056


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Yura
★    

Belarus,
2017-12-08 13:55
(2323 d 12:21 ago)

@ Helmut
Posting: # 18047
Views: 3,138
 

 theta0 within PE-constraints [theta1, theta2]

Hi Helmut
yes, I did so at once ;-)
Regards
UA Flag
Activity
 Admin contact
22,986 posts in 4,823 threads, 1,667 registered users;
87 visitors (0 registered, 87 guests [including 8 identified bots]).
Forum time: 03:17 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5